This digest version of the JCS 2015 guidelines provides recommendations for the clinical use of therapeutic drug monitoring for cardiovascular drugs to individualize and optimize pharmacotherapy.
Supports TDM for individualized cardiovascular pharmacotherapy; extends JCS 2015 recommendations into clinical and research practice.
CQ2 Does blood drug concentration monitoring of antiarrhythmic drugs help reduce ADRs in patients with arrhythmia who are receiving antiarrhythmic drugs? .............. 588 CQ3 Can we shorten the time to achieve an optimal dosage regimen by blood drug concentration monitoring of antiarrhythmic drugs in patients with arrhythmia?...... 588 HTU1 When should blood samples be taken to monitor blood concentrations of antiarrhythmic drugs? ........... 588 HTU2 Is it possible to predict the peak and trough concentrations of a drug on the basis of the timing of blood sampling and the blood drug concentration? .........
No takes yet. Share an insight, caveat, or question.
Aonuma et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: